7 results about "Stable angina" patented technology

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

The present application relates to a kind of traditional Chinese medicine composition for treating coronary atherosclerotic disease stable angina, the traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: Radix Bupleuri 10-14 parts, Ramulus Cinnamomi 3-7 parts, Herba Agrimoniae 13-17 parts, Salvia Miltiorrhiza 13-17 parts, Radix Paeoniae Alba 3-7 parts, Rhizoma Pinelliae Praeparatum 4-8 parts, Radix Scophularae 3-7 parts, Radix Ginseng 3-7 parts, Radix Glycyrrhizae 1-5 parts, Zingiber officinale 3-7 parts, Fructus Jujubae 4-8 parts.The present application also provides the application of traditional Chinese medicine composition in the preparation of medicine for treating coronary atherosclerotic disease stable angina.The treatment principle of the present application is: regulating liver and unblocking yang, regulating qi and activating blood.The drugs in the present application are used together, and the effect is enhanced, can regulate Ying and Wei, regulate liver qi, unblock chest yang, and unblock blood vessels, so as to achieve the effect of preventing and treating stable angina pectoris of coronary heart disease.The present application can effectively improve the angina pectoris symptoms of patients with stable angina pectoris of coronary heart disease, improve the quality of life of patients, has certain clinical value, and is worth further research and promotion.

This invention discloses a multifunctionalized pyridine compound, its preparation method, and its applications, belonging to the fields of pharmaceutical intermediates and organic synthesis. The invention uses α-allyl-p-toluenesulfonylmethylene isonitrile and substance A as raw materials, and a free radical cyclization reaction is carried out under the action of a catalyst to obtain a highly functionalized pyridine compound, as shown in formula (Ⅰ). Substance A is phenylboronic acid, cyclohexylboronic acid, [1,1'-biphenyl]-4-boronic acid, p-methylphenylboronic acid, m-methylphenylboronic acid, o-methylphenylboronic acid, p-cyanophenylboronic acid, thiophene-3-boronic acid, or cyclopropylboronic acid. The method of this invention not only has very broad substrate tolerance, inexpensive and readily available raw materials, and a simple reaction process suitable for large-scale synthesis, but also provides a new method for pharmaceutical chemical synthesis. Furthermore, due to the high functionalization and special structure of the pyridine compound, it exhibits better efficacy in treating chronic stable angina pectoris, central respiratory depression and circulatory failure, and in the treatment of various organoiodinated phosphate poisonings.

The invention relates to a heart-nourishing Damwaitomixic pill and a preparation method thereof. The heart-nourishing Damwaemixic pill comprises a pill core, wherein the pill core comprises mixed powder, clear paste and an adhesive; the mixed powder comprises medicine powder and dry auxiliary materials; the adhesive is prepared according to the following steps: mixing slurry A and slurry B; the pulp A comprises starch and a first batch of apple pulp; the pulp B comprises a second batch of apple pulp subjected to heating treatment; the mass ratio of the apple pulp to the starch is 390: (78-97.5); the mass ratio of the medicinal powder to the sum of the dry auxiliary materials and the starch is 1: (0.6-1); the ratio of the sum of the mass of the medicinal powder and the starch to the sum of the mass of the clear paste and the apple pulp is 1: (0.7-0.9). The heart-nourishing Damwaitomixic pill disclosed by the invention is low in sugar content, proper in disintegration time, good in stability and convenient to store and carry, and can be used as a medicine for treating or preventing stable angina pectoris and chronic heart failure.

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

This application discloses a method, apparatus, device, and storage medium for pushing cardiac rehabilitation prescriptions to patients with stable angina pectoris. The method includes: acquiring original patient medical data from at least one external subsystem via an asynchronous parallel interface; determining snapshot information of the patient's status under various predefined cardiac rehabilitation rules based on the original patient medical data; correcting at least one of the exercise prescription parameters, medication prescription parameters, nutritional prescription parameters, psychological prescription parameters, and smoking cessation prescription parameters in the corresponding rehabilitation prescription based on the snapshot information of the patient's status, thereby determining rehabilitation prescription information; predicting the correction scheme and resource scheduling scheme for rehabilitation activities against preset long-term goals in the corresponding event nodes based on the original patient data and rehabilitation prescription information, thereby determining correction prescription information and resource scheduling prescription information; and pushing the rehabilitation prescription information, correction prescription information, and resource scheduling prescription information to multiple terminals for visual display.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.